Generative Unconstrained Intelligence Drug Engineering (GUIDE) collaboration between U.S. interagency, academic and industry partners
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
W6QK ACC-APG
Contract Value
Not provided
Codes & Classification
Solicitation Number
W911SR-25-S-GUIDE
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Classification Code
AC13
Additional Details
The U.S. Army, through the Army Contracting Command - Aberdeen Proving Ground (ACC-APG), Edgewood Contracting Division, has issued a Special Notice (Procurement Identifier: W911SR-25-S-GUIDE) inviting qualified entities to participate in the Generative Unconstrained Intelligence Drug Engineering (GUIDE) program. This initiative is spearheaded by the Joint Project Lead Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies (JPL-CBRND-EB), whose mission is to accelerate the delivery of medical countermeasures to protect warfighters against a broad spectrum of chemical, biological, radiological, and nuclear threats.
GUIDE is an integrated computational and experimental platform designed to expedite the development of medical countermeasures. Leveraging advanced simulation and machine learning, the program aims to enhance preparedness and enable rapid response capabilities. The platform supports the discovery and design of biological products, such as monoclonal antibodies and vaccines, as well as small molecule drugs. A key focus is the simultaneous optimization of critical quality attributes—including safety, efficacy, manufacturability, and pharmacokinetics/pharmacodynamics—while also addressing essential design considerations related to developability and biophysical properties.
This program is a collaborative effort involving U.S. interagency partners, academia, and industry, and is closely aligned with related initiatives such as Accelerated Antibodies, Rapid Access to Products in Development (RAPID), Vaccine Acceleration by Modular Progression (VAMP), and Rapid Acquisition and Investigation of Drugs for Repurposing (RAIDR). Additional program information is available at the provided SharePoint link.
Participation in the GUIDE program is governed by a Participant Basic Agreement (PBA), which is available to entities that demonstrate technical relevance in the development of medical countermeasures. Interested parties are required to submit a request for participation via email to the designated points of contact, including evidence of their technical capabilities. Submissions that are purely promotional or marketing in nature are discouraged. The program office will review all requests to determine technical suitability before extending invitations to participate.
Awards under the GUIDE program may be made pursuant to authorities 10 U.S.C. 4022 and 10 U.S.C. 4023, and will not be subject to the Competition in Contracting Act of 1984, FAR Part 6, or other FAR-based regulations. This approach allows for flexible and rapid engagement with qualified partners.
The place of performance for GUIDE-related activities is Frederick, Maryland. The applicable NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences, except Nanotechnology and Biotechnology), and the Product Service Code is AC13.
All prospective participants must be registered in the System for Award Management (SAM) and maintain current, accurate, and complete information throughout the contract lifecycle. The government will not consider entities that have engaged in criminal, fraudulent, or seriously improper conduct.
This notice is for planning purposes only and does not constitute a commitment by the government. No compensation will be provided for information submitted in response to this announcement.
For further information or to express interest in participation, contact the primary points of contact:
- Joseph McCaffery ([email protected])
- Keith Pereira ([email protected])
Interested parties are encouraged to direct all technical and administrative inquiries to these contacts to facilitate communication regarding this opportunity.
For full details, refer to the official notice at: https://sam.gov/opp/7d3f105a09734cbb9b3742fbaca5998f/view